12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

All-In-One: Clinical trial started

Svelte began the international DIRECT II trial to compare its IDS vs. the Resolute Integrity drug-eluting stent in 159 patients. Medtronic Inc. (NYSE:MDT, Minneapolis,...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >